Cargando…
利妥昔单抗联合二线方案治疗七例复发难治性霍奇金淋巴瘤患者疗效观察
OBJECTIVE: To investigate the efficacy and safety of Rituximab combined with second line regimen for treatment of relapsed and refractory Hodgkin lymphoma. METHODS: Seven patients with relapsed and refractory Hodgkin lymphoma were treated with Rituximab combined with second line regimen. Among them,...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342643/ https://www.ncbi.nlm.nih.gov/pubmed/26304082 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.07.011 |
Ejemplares similares
-
来那度胺联合利妥昔单抗治疗13例老年或复发/难治性B细胞非霍奇金淋巴瘤患者的疗效观察
Publicado: (2017) -
IGEV方案治疗复发难治性霍奇金淋巴瘤的临床研究
Publicado: (2018) -
DICE方案治疗97例复发/难治非霍奇金淋巴瘤患者的疗效及生存分析
Publicado: (2016) -
大剂量地塞米松联合小剂量利妥昔单抗作为二线方案治疗65例原发免疫性血小板减少症患者的临床观察
Publicado: (2015) -
含利妥昔单抗联合方案治疗难治/复发血栓性血小板减少性紫癜10例临床分析
Publicado: (2018)